Abbott and Medtronic Partner for Enhanced Diabetes Management
Unlocking Continuous Glucose Monitoring with World-Leading Technologies
Partnership Overview
Abbott (NYSE: ABT) and Medtronic have forged a groundbreaking global partnership to revolutionize the management of diabetes. This partnership brings together two industry leaders in glucose sensing and insulin delivery, offering a comprehensive solution for people with diabetes.
Collaborative Innovation
The partnership aims to integrate Abbott's continuous glucose monitoring (CGM) sensors with Medtronic's insulin delivery devices. Abbott's FreeStyle Libre sensors, known for their accuracy and extended wear time, will provide a reliable foundation for precise glucose monitoring.
By combining these technologies, the partnership aims to automate insulin delivery, reduce hypoglycemia and hyperglycemia events, and improve overall blood glucose control for people with diabetes.
Industry-Leading Expertise
"This partnership pairs two global leaders in glucose sensing technology and insulin delivery," said Jared Watkin, executive vice president of Abbott Diabetes Care. "Together, we will harness our collective expertise to provide a more seamless and comprehensive solution for people with diabetes."
Impact on Diabetes Management
The integrated system is expected to empower people with diabetes with real-time insights into their glucose levels, enabling them to make informed decisions about their medication and lifestyle. This enhanced monitoring and control can lead to improved health outcomes and a better quality of life.
Comments